JCI
US$ 21.69
depression semaglutide Weight loss drugs linked to lower likelihood of and anxiety diagnoses: Study The GLP-1 semaglutide (#Ozempic) failed
Description
SELECT (NEJM 2023) established the CV benefit: 17,604 adults with established CVD and overweight or obesity, 20% reduction in major cardiovascular events over a mean 40 months
10 Engineering for a Longer Life Twice-daily injection was never going to be a mass-market product
The effect of glucagon like peptide-1 receptor agonist on behavioral despair and anxiety-like behavior in ovariectomized rats: modulation of BDNF/CREB, Nrf2 and lipocalin 2
It is not intended for human consumption, self-administration, treatment, weight-loss use or personal use
